Logo for ArriVent BioPharma Inc

ArriVent BioPharma Investor Relations Material

Latest events

Logo for ArriVent BioPharma

Q1 2024

8 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from ArriVent BioPharma Inc

Access all reports
ArriVent BioPharma Inc. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of innovative medicines to meet the unmet medical needs of patients with cancers. The company specializes in developing targeted cancer therapies, including for non-small-cell lung cancer (NSCLC) and other solid tumors. A key product in its pipeline is Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor.